Information Provided By: 
Fly News Breaks for August 30, 2019
TNXP
Aug 30, 2019 | 15:33 EDT
Roth Capital analyst Scott Henry lowered his price target for Tonix Pharmaceuticals to $1.30 from $4.00 while maintaining a Buy rating on the shares. While dilution from the company's equity offering in July was "painful," it should have enough cash runway into a data release, Henry tells investors in a research note.
News For TNXP From the Last 2 Days
There are no results for your query TNXP
